Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Icecure Medical ( (ICCM) ) has issued an update.
On October 16, 2025, IceCure Medical Ltd. announced the termination of Ms. Galit Malik, the Vice President of Operations and Services, effective January 15, 2026. The company clarified that the termination was not due to any disagreements related to its operations, policies, or practices. This move could potentially impact the company’s operational dynamics, although no immediate implications for stakeholders were mentioned.
The most recent analyst rating on (ICCM) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by significant financial challenges, including declining revenues and substantial losses. While there is optimism around regulatory progress and clinical achievements, these are overshadowed by weak financial performance and valuation concerns.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. operates in the medical technology industry, focusing on the development and commercialization of minimally invasive cryoablation systems for the treatment of tumors. The company’s primary product is the ProSense system, which is designed for the treatment of breast, lung, and other cancers.
Average Trading Volume: 2,354,708
Technical Sentiment Signal: Sell
Current Market Cap: $56.72M
See more insights into ICCM stock on TipRanks’ Stock Analysis page.